Latest MDTN news and sentiment

Sonus Microsystems and Medtronic Partner to Advance AI-Powered Maternal Health Monitoring

Partnership will pair Medtronic vital-sign monitoring with Sonus's ultrasound AI platform in field studies, funded by the Gates Foundation VANCOUVER, British Columbia and LAFAYETTE, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Sonus Microsystems today announced a collaboration withMedtronic, the global leader in healthcare technology, to integrate the Sonus Patch™, an AI-powered wearable ultrasound platform, with technology from the Acute Care & Monitoring operating unit at Medtronic. The collaboration will evaluate an integrated, non-invasive monitoring system in field studies in Kenya. Together

Jim Cramer Calls Medtronic (MDT) a “Quandary” as Growth Surges and Diabetes Exit Nears

Jim Cramer called Medtronic plc (NYSE:MDT) a "quandary" on the September 8 episode of Mad Money, as he said: At the same time, there's some tremendous healthcare companies in bull market mode… Here's one that's a quandary, Medtronic. Medtronic, the medical device company, shocked us with a big upside surprise and a major increase in organic growth. It's separating its worrisome diabetes division by the end of the year. I don't want to be in a diabetes division in a world where GLP-1s are ascendant. The stock is now where it was when it reported. Yet, it is a vastly improved year-over-year busi

Medtronic’s (MDT) Heart Devices Are Suddenly Outgrowing The Rest Of Med-Tech

On September 1, Medtronic (NYSE:MDT) reported fiscal 2027 first-quarter results that blew past its own guidance, with revenue of $9.8 billion and organic growth of 13.7%. An extra selling week included in the quarter, which ended July 31, added roughly $570 million to that figure. Still, even stripping that out, management called it the strongest quarter in nearly eight years. The company used the beat to raise its full-year outlook.Medtronic's (MDT) Heart Devices Are Suddenly Outgrowing The Rest Of Med-Tech A Heart Business On Fire Cardiovascular revenue jumped 18.9% organically to $3.9 billi

Medtronic Raised its Outlook as Heart Devices Accelerate, But Can the Momentum Last?

Medtronic plc (NYSE:MDT) entered fiscal 2027 expecting solid growth. One quarter later, strong demand for its cardiovascular devices has given management enough confidence to raise that outlook. The company increased its organic revenue growth forecast and lifted the lower end of its adjusted earnings range after beating quarterly expectations. Its cardiovascular business was the standout, helped by rapid growth in pulsed field ablation products used to treat irregular heart rhythms. Medtronic (NYSE:MDT) is also investing in heart-valve technology and surgical robotics to strengthen its longer

Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum

Medtronic plc MDT raised its fiscal 2027 outlook after first-quarter earnings and revenues exceeded expectations and growth accelerated across its major businesses. The stronger start gives management more confidence in the full-year trajectory. The bigger question is whether that momentum can persist as newer growth platforms scale and cost pressures remain in play. The quarter improved the earnings setup, but sustaining the pace will require consistent execution across several businesses. MDT's First Quarter Beat Reset 2027 Expectations Adjusted earnings were $1.45 per share, up 15.1% year o

Is Medtronic Worth Buying as Growth Improves but Risks Stay Elevated?

Medtronic plc MDT is entering fiscal 2027 with broader revenue growth, higher earnings guidance and a valuation near its historical norm. Those positives improve the investment case, but they do not remove questions around margins, foreign exchange and execution. The stock therefore sits between improving fundamentals and still-elevated operating risk. Investors have more evidence that growth is becoming durable, yet the current setup still argues for selectivity rather than an aggressive stance. Medtronic's Growth Case Is Getting Stronger Fiscal 2027 first-quarter organic revenue increased 13

Medtronic raises FY27 outlook after reporting strong Q1 growth

Medtronic has reported revenues of around $9.8bn in Q1 of fiscal year 2027 (FY27) driven by double-digit growth across its key business segments, prompting the company to raise its FY27 outlook. With Q1 performance corresponding to year-over-year (YoY) growth of 13.7%, the medtech giant now expects organic revenue growth for FY27 to land in the 7.25% to 7.75% range, up from 6.75% to 7.25% previously, and with earnings anticipated to come in at $5.94-$6 per share versus $5.90-$6 previously. Medtronic's cardiovascular business was its top performer in Q1, with worldwide revenues of around $3.9bn

How To Earn $500 A Month From Medtronic Stock Ahead Of Q1 Earnings

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Medtronic plc will release its first earnings report before the opening bell on Tuesday, Sept. 1. Analysts expect the company to report quarterly earnings of $1.39 per share, up from $1.26 per share in the year-ago period. The consensus estimate for Medtronic's quarterly revenue is $9.54 billion. It reported $8.54 billion last year, according to Benzinga Pro. Ahead of quarterly earnings, TD Cowen analyst Joshua Jennings maintained Medtronic at Buy on Friday and raised the price target from $100

Medtronic Flirts With A Breakout As Its Spinoff, MiniMed, Hits A Record

Medtronic stock popped Tuesday as its diabetes spinoff MiniMed rallied after both lifted their full-year guidance. Continue Reading

Medtronic’s Stars Are Aligning for a Price Recovery

Key Points Interested in Medtronic PLC? Here are five stocks we like better. Medtronic reported strong fiscal Q1 2027 results, with revenue up 13.7% to over $9.75 billion and raised guidance for the year ahead. The company yields over 3% and is one dividend increase away from achieving Dividend King status, attracting long-term institutional investors. Analysts maintain a bullish Moderate Buy consensus on Medtronic, with 27 analysts tracking the stock and no Sell ratings currently logged. Medtronic (NYSE: MDT) is a good buy in late 2026 because stars such as value, growth, guidance, partnershi

Medtronic Q1 Earnings & Revenues Top Estimates, Stock Up in Pre-Market

Medtronic plc MDT reported first-quarter fiscal 2027 adjusted earnings per share (EPS) of $1.45 per share, which rose 15.1% year over year and topped the Zacks Consensus Estimate by 4.32%. The metric excludes certain one-time adjustments, including amortization of intangible assets, restructuring and associated costs, as well as acquisition and divestiture-related items. On a GAAP basis, EPS came in at $1.14, up from 81 cents a year earlier. MDT's Q1 Revenues Revenues rose 13.7% year over year to $9.76 billion and beat the consensus mark by 3.02%. The quarter included an extra fiscal week, whi

Medtronic Q1 Earnings Call Highlights

Key Points Interested in Medtronic PLC? Here are five stocks we like better. Medtronic raised its fiscal 2027 outlook after first-quarter revenue rose 13.7% to $9.8 billion and adjusted EPS reached $1.45, beating expectations. The company now expects 7.25%–7.75% organic revenue growth and adjusted EPS of $5.94–$6.00 for the full year. Cardiovascular led operating momentum, with revenue up 19% and Cardiac Ablation Solutions surging 88% globally and 139% in the U.S., driven by Sphere-9 and Affera adoption. CRM also grew 15% and gained global market share. Medtronic continues investing in growth,

Medtronic Raises Full-Year Outlook Following Fiscal First-Quarter Beat

Medtronic (MDT) lifted its full-year outlook on Tuesday as the medical-device maker reported better- PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Medtronic Tops Earnings Estimates and Makes $700M Robot Surgeon Investment. Is It Gaining on Intuitive Surgical?

Medtronic stock advances after the company posts better-than-expected quarterly earnings, raises revenue guidance, and announces a $700 million investment. Continue Reading

Medtronic jumps on earnings beat and raised guidance

Investing.com -- Medtronic plc (NYSE: MDT) reported first-quarter fiscal 2027 results that exceeded analyst expectations, with shares rising 5% as the medical device maker raised its full-year outlook on strength across its portfolio. The company posted adjusted EPS of $1.45, beating the consensus estimate of $1.39 by $0.06. Revenue reached $9.8 billion, up 13.7% YoY and ahead of the $9.55 billion analyst estimate. Medtronic raised its fiscal 2027 organic revenue growth guidance to 7.25% to 7.75%, up from prior guidance of 6.75% to 7.25%. The company also increased its full-year adjusted EPS g

Medtronic in Charts: Double-digit growth broadens across key segments in FQ1

[https://static.seekingalpha.com/uploads/2026/9/1/saupload_MDT1.png] [https://static.seekingalpha.com/uploads/2026/9/1/saupload_MDT2.png] [https://static.seekingalpha.com/uploads/2026/9/1/saupload_MDT3.png] [https://static.seekingalpha.com/uploads/2026/9/1/saupload_MDT4.png] MORE ON MEDTRONIC PLC * Medtronic: The CAS Catalyst Can Close A 27% Peer Discount [https://seekingalpha.com/article/4939277-medtronic-the-cas-catalyst-can-close-a-27-percent-peer-discount] * Medtronic: Riding On Next-Gen Tech Medical Devices [https://seekingalpha.com/article/4938832-medtronic-riding-on-next-gen-tech-medica

Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance

Strength across the company's largest franchises, new growth platforms, and recent portfolio investments support the long-term growth trajectory GALWAY, Ireland, Sept. 1, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2027 (FY27), which ended July 31, 2026. Key Highlights Revenue of $9.8 billion, increased 13.7% as reported and 13.7% organic, roughly 200 basis points above guidance midpoint GAAP diluted EPS of $1.14; non-GAAP diluted EPS of $1.45, ahead of guidance Raising FY2

Medtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery

Partnership expands Medtronic's robotic-assisted surgery portfolio to expand access globally and gives surgeons and health systems more choice and flexibility $700 million investment includes rights to distribute Cornerstone Robotics' Sentire™ surgical system in select markets outside the U.S. Sentire will be a strong complement to Medtronic's Hugo™ robotic-assisted surgery (RAS) system, creating a unique portfolio of robotic solutions GALWAY, Ireland, Sept. 1, 2026 /PRNewswire/ -- Medtronic, a global leader in healthcare technology, today announced a strategic partnership with Cornerstone Rob

Informe de resultados: Medtronic supera estimaciones del Q1 2026 y mejora perspectivas